- Home
- Equipment
- canada british columbia
- life sciences
Show results for
Refine by
Life Sciences Equipment Supplied In Canada British Columbia
8 equipment items found
Manufactured by:RepliCel Life Sciences based inVancouver, BRITISH COLUMBIA (CANADA)
DermaPrecise is our next-generation dermal injector. DermaPrecise™ is the world's first motorized injection device with programmable depth and volume, a built-in Peltier element for pre-injection numbing of the skin and interchangeable needle head configurations. It is designed to deliver a variety of injectable substances in and under the skin with an array of needle configurations, ...
Manufactured by:RepliCel Life Sciences based inVancouver, BRITISH COLUMBIA (CANADA)
RCS-01 is a proprietary autologous cell therapy being developed to rejuvenate aging or UV-damaged skin.* *This product is currently in clinical testing and not yet commercially available. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells - a type of fibroblast cell - isolated from the hair follicle to repair and regenerate tissue. Though several cell types are ...
Manufactured by:RepliCel Life Sciences based inVancouver, BRITISH COLUMBIA (CANADA)
RCT-01 is a proprietary autologous cell therapy being developed to treat chronically damaged tendons. * *This product is currently in clinical testing and not yet commercially available. RCT-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells - a type of fibroblast cell - isolated from the hair follicle to repair and regenerate tissue. Though several cell types are ...
Manufactured by:RepliCel Life Sciences based inVancouver, BRITISH COLUMBIA (CANADA)
RCH-01 is a proprietary autologous cell therapy being developed to treat pattern baldness.* *This product is currently in clinical testing and not yet commercially available. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. Though several cell types are involved, dermal sheath cup cells, located at base of ...
Manufactured by:Augurex Life Sciences Corp. based inVancouver, BRITISH COLUMBIA (CANADA)
Citrullination is a highly relevant post-translational modification of proteins that occurs in RA and certain other conditions. In the extracellular space, 14-3-3η becomes citrullinated (cit) in the presence of peptidylarginine deiminases (PAD) enzymes and this extracellular modified form of the protein, cit-14-3-3η, also elicits an auto-immune response that generates cit-14-3-3η ...
Manufactured by:Augurex Life Sciences Corp. based inVancouver, BRITISH COLUMBIA (CANADA)
14-3-3η is not normally present outside of cells. Therefore, in the disease state, the body views it as foreign and mounts an immune response in an attempt to clear it. This immune response generates14-3-3η specific auto-antibodies that are measureable in blood and provide complementary disease information to the 14-3-3η protein. In particular, they are highly specific in very early ...
Manufactured by:Augurex Life Sciences Corp. based inVancouver, BRITISH COLUMBIA (CANADA)
In the development of RA and other inflammatory types of arthritis, multiple factors contribute to disease processes to varying degrees in different patients. 14-3-3η is recognized as a new factor within this process and represents a rationale drug target for personalized medicine alongside its 14-3-3η companion biomarker portfolio described above. Augurex preclinical animal studies to ...
Manufactured by:Augurex Life Sciences Corp. based inVancouver, BRITISH COLUMBIA (CANADA)
Extracellular 14-3-3η protein is a potent ligand and activator of intracellular signalling pathways that lead to the up-regulation of inflammation and joint damage factors involved in RA pathogenesis. The 14-3-3η blood test is clinically available as a diagnostic test whereby a positive result indicates a 5 to 50 times greater likelihood of having RA and informs joint damage prognosis and ...